<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03135834</url>
  </required_header>
  <id_info>
    <org_study_id>B1971057</org_study_id>
    <secondary_id>2016-004421-17</secondary_id>
    <nct_id>NCT03135834</nct_id>
  </id_info>
  <brief_title>A Trial to Describe the Immunogenicity and Safety of 2 Doses of Bivalent rLP2086 (Trumenba) and a Pentavalent Meningococcal Vaccine in Healthy Subjects &gt;=10 to &lt;26 Years of Age.</brief_title>
  <official_title>A Phase 3, Randomized, Active-controlled, Observer-blinded Study To Assess The Immunogenicity, Safety, And Tolerability Of Bivalent Rlp2086 When Administered As A 2-dose Regimen And A First-in-human Study To Describe The Immunogenicity, Safety, And Tolerability Of A Bivalent Rlp2086-Containing Pentavalent Vaccine (Menabcwy) In Healthy Subjects&gt;=10 To &lt;26 Years Of Age</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pfizer</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Pfizer</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is examining safety and immunogenicity of 2 doses of Trumenba administered on a
      0-,6- month schedule. This trial is also studyng safety and immunogenicity of a meningococcal
      pentavalent vaccine.
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">April 24, 2017</start_date>
  <completion_date type="Anticipated">December 28, 2022</completion_date>
  <primary_completion_date type="Anticipated">December 5, 2018</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of Participants With &gt;=4 Fold Rise in Serum Bactericidal Assay Using Human Complement (hSBA) for 4 Primary MnB Strains and Composite Response (hSBA &gt;=Lower Limit of Quantification [LLOQ] for All 4 Primary MnB Strains Combined) for Groups 2 + 4</measure>
    <time_frame>Before Vaccination 1 and 1 Month after Vaccination 2</time_frame>
    <description>Assess B response after two doses of Trumenba</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants Reporting Local Reactions (LRs) Within 7 Days After First Vaccination for Groups 2 and 4 combined</measure>
    <time_frame>Within 7 Days after first vaccination</time_frame>
    <description>Describe local reactions after first dose of Trumenba</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants Reporting Local Reactions (LRs) Within 7 Days After Second Vaccination for Groups 2 and 4 combined</measure>
    <time_frame>Within 7 Days after second vaccination</time_frame>
    <description>Describe local reactions after second dose of Trumenba.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants Reporting Systemic Events (SEs) and Antipyretic Use Within 7 Days After First Vaccination for Groups 2 and 4 combined</measure>
    <time_frame>Within 7 Days after first vaccination</time_frame>
    <description>Describe systemic events and use of anti-pyretic medication after first dose of Trumenba.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants Reporting Systemic Events (SEs) and Antipyretic Use Within 7 Days After Second Vaccination for Groups 2 and 4 combined</measure>
    <time_frame>Within 7 Days after second vaccination</time_frame>
    <description>Describe systemic events and use of anti-pyretic medication after second dose of Trumenba.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants With at Least 1 Serious Adverse Event (SAE) Within 30 Days After First Vaccination for Groups 2 and 4 combined</measure>
    <time_frame>Within 30 days after first vaccination</time_frame>
    <description>Describe SAE frequency after first dose of Trumenba.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants With at Least 1 Serious Adverse Event (SAE) Within 30 Days After Second Vaccination for Groups 2 and 4 combined</measure>
    <time_frame>Within 30 days after second vaccination</time_frame>
    <description>Describe SAE frequency after second dose of Trumenba.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants With at Least 1 Serious Adverse Event (SAE) Within 30 Days After Any Vaccination for Groups 2 and 4 combined</measure>
    <time_frame>Within 30 days after any vaccination in Stage 1</time_frame>
    <description>Describe SAE frequency after any dose of Trumenba in Stage 1.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants With at Least 1 Serious Adverse Event (SAE) During the Stage 1 Vaccination Phase for Groups 2 and 4 combined</measure>
    <time_frame>From the first vaccination up to 1 month after the second vaccination</time_frame>
    <description>Describe SAE frequency during the Stage 1 vaccination phase in the Trumenba vaccination groups.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants With at Least 1 Serious Adverse Event (SAE) During the Stage 1 Follow-up Phase for Groups 2 and 4 combined</measure>
    <time_frame>From 1 month after second vaccination up to 6 months after the second vaccination</time_frame>
    <description>Describe SAE frequency during the Stage 1 follow-up phase in the Trumenba vaccination groups.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants With at Least 1 Serious Adverse Event (SAE) Throughout Stage 1 of the Study for Groups 2 and 4 combined</measure>
    <time_frame>From the first vaccination up to 6 months after the second vaccination</time_frame>
    <description>Describe SAE frequency during the Stage 1 in the Trumenba vaccination groups.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants With at Least 1 Medically Attended AE Within 30 Days After First Vaccination for Groups 2 and 4 combined</measure>
    <time_frame>Within 30 days after first vaccination</time_frame>
    <description>Describe MAE frequency after first dose of Trumenba.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants With at Least 1 Medically Attended AE Within 30 Days After Second Vaccination for Groups 2 and 4 combined</measure>
    <time_frame>Within 30 days after second vaccination</time_frame>
    <description>Describe MAE frequency after second dose of Trumenba.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants With at Least 1 Medically Attended AE Within 30 Days After Any Vaccination for Groups 2 and 4 combined</measure>
    <time_frame>Within 30 days after any vaccination</time_frame>
    <description>Describe MAE frequency after any dose of Trumenba in Stage 1.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants With at Least 1 Medically Attended AE During the Stage 1 Vaccination Phase for Groups 2 and 4 combined</measure>
    <time_frame>From the first vaccination up to 1 month after the second vaccination</time_frame>
    <description>Describe MAE frequency during the Stage 1 vaccination phase in the Trumenba vaccination groups.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants With at Least 1 Medically Attended AE During the Stage 1 Follow-up Phase for Groups 2 and 4 combined</measure>
    <time_frame>From 1 month after second vaccination up to 6 months after the second vaccination</time_frame>
    <description>Describe MAE frequency during the Stage 1 follow-up phase in the Trumenba vaccination groups.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants With at Least 1 Medically Attended AE Throughout Stage 1 of the Study for Groups 2 and 4 combined</measure>
    <time_frame>From the first vaccination up to 6 months after the second vaccination</time_frame>
    <description>Describe MAE frequency during the Stage 1 in the Trumenba vaccination groups.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants With at Least 1 Newly Diagnosed Chronic Medical Condition Within 30 Days After First Vaccination for Groups 2 and 4 combined</measure>
    <time_frame>Within 30 days after first vaccination</time_frame>
    <description>Describe NDCMC frequency after first dose of Trumenba.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants With at Least 1 Newly Diagnosed Chronic Medical Condition Within 30 Days After Second Vaccination for Groups 2 and 4 combined</measure>
    <time_frame>Within 30 days after second vaccination</time_frame>
    <description>Describe NDCMC frequency after second dose of Trumenba.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants With at Least 1 Newly Diagnosed Chronic Medical Condition Within 30 Days After Any Vaccination for Groups 2 and 4 combined</measure>
    <time_frame>Within 30 days after any vaccination</time_frame>
    <description>Describe NDCMC frequency after any dose of Trumenba in Stage 1</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants With at Least 1 Newly Diagnosed Chronic Medical Condition During the Stage 1 Vaccination Phase for Groups 2 and 4 combined</measure>
    <time_frame>From the first vaccination up to 1 month after the second vaccination</time_frame>
    <description>Describe NDCMC frequency during the Stage 1 vaccination phase in the Trumenba vaccination groups.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants With at Least 1 Newly Diagnosed Chronic Medical Condition During the Stage 1 Follow-up Phase for Groups 2 and 4 combined</measure>
    <time_frame>From 1 month after second vaccination up to 6 months after the second vaccination</time_frame>
    <description>Describe NDCMC frequency during the Stage 1 follow-up phase in the Trumenba vaccination groups.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants With at Least 1 Newly Diagnosed Chronic Medical Condition Throughout Stage 1 of the Study for Groups 2 and 4 combined</measure>
    <time_frame>From the first vaccination up to 6 months after the second vaccination</time_frame>
    <description>Describe NDCMC frequency during the Stage 1 in the Trumenba vaccination groups.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants With at Least 1 Adverse Event (AE) Within 30 Days After First Vaccination for Groups 2 and 4 combined</measure>
    <time_frame>Within 30 days after first vaccination</time_frame>
    <description>Describe AE frequency after first dose of Trumenba.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants With at Least 1 Adverse Event (AE) Within 30 Days After Second Vaccination for Groups 2 and 4 combined</measure>
    <time_frame>Within 30 days after second vaccination</time_frame>
    <description>Describe AE frequency after second dose of Trumenba.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants With at Least 1 Adverse Event (AE) Within 30 Days After Any Vaccination for Groups 2 and 4 combined</measure>
    <time_frame>Within 30 days after any vaccination</time_frame>
    <description>Describe AE frequency after any dose of Trumenba in Stage 1</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants With at Least 1 Adverse Event (AE) During the Stage 1 Vaccination Phase for Groups 2 and 4 combined</measure>
    <time_frame>From the first vaccination up to 1 month after the second vaccination</time_frame>
    <description>Describe AE frequency during the Stage 1 vaccination phase in the Trumenba vaccination groups.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants Reporting at Least 1 Immediate Adverse Event (AE) After First Vaccination for Groups 2 and 4 combined</measure>
    <time_frame>Within 30 minutes after first vaccination</time_frame>
    <description>Describe immediate AE frequency after first dose of Trumenba.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants Reporting at Least 1 Immediate Adverse Event (AE) After Second Vaccination for Groups 2 and 4 combined</measure>
    <time_frame>Within 30 minutes after second vaccination</time_frame>
    <description>Describe immediate AE frequency after second dose of Trumenba.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Days Participants Missed School or Work Due to AE During the Stage 1 Vaccination Phase for Groups 2 and 4 combined</measure>
    <time_frame>From the first vaccination up to 1 month after the second vaccination</time_frame>
    <description>Describe the number of days missed from school or work due to an AE during the Stage 1 vaccination phase in Trumenba vaccination groups.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With hSBA Titers &gt;=LLOQ for 4 Primary MenB Test Strains Before First Vaccination and 1 Month After the Second Bivalent rLP2086 Vaccination: Groups 2 and 4 combined</measure>
    <time_frame>Before Vaccination 1 and 1 Month after Vaccination 2</time_frame>
    <description>Describe B response after two doses of Trumenba.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With hSBA Titers &gt;=1:4,&gt;=1:8,&gt;=1:16,&gt;=1:32,&gt;=1:64,&gt;=1:128 for 4 Primary MenB Test Strains Before the First Vaccination and 1 Month After Second Bivalent rLP2086 Vaccination: Groups 2 and 4 combined</measure>
    <time_frame>Before Vaccination 1 and 1 Month after Vaccination 2</time_frame>
    <description>Describe B response after two doses of Trumenba.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>hSBA Geometric Mean Titers (GMTs) for 4 Primary MenB Test Strains Before First Vaccination and 1 Month After Second Bivalent rLP2086 Vaccination: Groups 2 and 4 combined</measure>
    <time_frame>Before Vaccination 1 and 1 Month after Vaccination 2</time_frame>
    <description>Describe B response after two doses of Trumenba.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With hSBA Titers &gt;= LLOQ for 10 Secondary MenB Strains Before First Vaccination and 1 Month After Second Bivalent rLP2086 Vaccination: Groups 2 and 4 combined</measure>
    <time_frame>Before Vaccination 1 and 1 Month after Vaccination 2</time_frame>
    <description>Describe B response (secondary strains) after two doses of Trumenba.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With hSBA Titers &gt;=1:4, &gt;=1:8, &gt;=1:16, &gt;=1:32, &gt;=1:64, &gt;=1:128 for Each of the 10 Secondary MenB Strains Before First Vaccination and 1 Month After the Second Bivalent rLP2086 Vaccination: Groups 2 and 4 combined</measure>
    <time_frame>Before Vaccination 1 and 1 Month after Vaccination 2</time_frame>
    <description>Describe B response (secondary strains) after two doses of Trumenba.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>GMTs for Each of the 10 Secondary MenB Strains Before First Vaccination and 1 Month After the Second Bivalent rLP2086 Vaccination: Groups 2 and 4 combined</measure>
    <time_frame>Before Vaccination 1 and 1 Month after Vaccination 2</time_frame>
    <description>Describe B response (secondary strains) after two doses of Trumenba.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With hSBA Titers &gt;=1:8 (or &gt;=LLOQ if higher) for ACWY Test Strains 1 Month After the First Vaccination: Groups 1, 2, 3 and 4</measure>
    <time_frame>1 Month after Vaccination 1</time_frame>
    <description>Describe ACWY response after 1 dose of MenACWY-CRM compared to 1 dose of MenABCWY</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With hSBA Titers &gt;=1:4,&gt;=1:8,&gt;=1:16,&gt;=1:32,&gt;=1:64,&gt;=1:128 for ACWY Test Strains 1 Month After First Vaccination: Groups 1, 2, 3 and 4</measure>
    <time_frame>1 Month after Vaccination 1</time_frame>
    <description>Describe ACWY response after 1 dose of MenACWY-CRM compared to 1 dose of MenABCWY</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>hSBA GMTs for ACWY Test Strains 1 Month After First Vaccination: Groups 1, 2, 3 and 4</measure>
    <time_frame>1 Month after Vaccination 1</time_frame>
    <description>Describe ACWY response after 1 dose of MenACWY-CRM compared to 1 dose of MenABCWY</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With hSBA Titers &gt;=1:8 (or &gt;=LLOQ if higher) for ACWY Test Strains 1 Month After the First Vaccination in Groups 2 and 4, and 1 Month After Second Vaccination in Groups 1 and 3</measure>
    <time_frame>1 Month after Vaccination 1 (Groups 2 and 4), and 1 Month after Vaccination 2 (Groups 1 and 3)</time_frame>
    <description>Describe ACWY response after 1 dose of MenACWY-CRM compared to 2 doses of MenABCWY</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With hSBA Titers &gt;=1:4,&gt;=1:8,&gt;=1:16,&gt;=1:32,&gt;=1:64,&gt;=1:128 for ACWY Test Strains 1 Month After the First Vaccination in Groups 2 and 4, and 1 Month After Second Vaccination in Groups 1 and 3</measure>
    <time_frame>1 Month after Vaccination 1 (Groups 2 and 4), and 1 Month after Vaccination 2 (Groups 1 and 3)</time_frame>
    <description>Describe ACWY response after 1 dose of MenACWY-CRM compared to 2 doses of MenABCWY</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>hSBA GMTs for ACWY Test Strains 1 Month After the First Vaccination in Groups 2 and 4, and 1 Month After Second Vaccination in Groups 1 and 3</measure>
    <time_frame>1 Month after Vaccination 1 (Groups 2 and 4), and 1 Month after Vaccination 2 (Groups 1 and 3)</time_frame>
    <description>Describe ACWY response after 1 dose of MenACWY-CRM compared to 2 doses of MenABCWY</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With &gt;=4 Fold Rise in hSBA for 4 Primary MnB Strains and Composite Response (hSBA &gt;=LLOQ for All 4 Primary MnB Strains Combined) for Groups 1 and 3 combined, and Groups 2 and 4 combined</measure>
    <time_frame>Before Vaccination 1 and 1 Month after Vaccination 2</time_frame>
    <description>Describe B response after two doses of Trumenba compared to two doses of MenABCWY</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With hSBA Titers &gt;=LLOQ for 4 Primary MenB Test Strains Before First Vaccination and 1 Month After the Second Vaccination: Groups 1 and 3 combined, and Groups 2 and 4 combined</measure>
    <time_frame>Before Vaccination 1 and 1 Month after Vaccination 2</time_frame>
    <description>Describe B response after two doses of Trumenba compared to two doses of MenABCWY</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With hSBA Titers &gt;=1:4,&gt;=1:8,&gt;=1:16,&gt;=1:32,&gt;=1:64,&gt;=1:128 for 4 Primary MenB Test Strains Before the First Vaccination and 1 Month After Second Vaccination: Groups 1 and 3 combined, and Groups 2 and 4 combined</measure>
    <time_frame>Before Vaccination 1 and 1 Month after Vaccination 2</time_frame>
    <description>Describe B response after two doses of Trumenba compared to two doses of MenABCWY</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>hSBA GMTs for 4 Primary MenB Test Strains Before First Vaccination and 1 Month After Second Vaccination: Groups 1 and 3 combined, and Groups 2 and 4 combined</measure>
    <time_frame>Before Vaccination 1 and 1 Month after Vaccination 2</time_frame>
    <description>Describe B response after two doses of Trumenba compared to two doses of MenABCWY</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With hSBA Titers &gt;=1:8 (or &gt;=LLOQ if higher) for ACWY Test Strains: Groups 1, 2, 3 and 4</measure>
    <time_frame>Before Vaccination 1, 1 Month after Vaccination 1, Before Vaccination 2, 1 Month after Vaccination 2</time_frame>
    <description>Describe ACWY response during Stage 1.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With hSBA Titers &gt;=1:4,&gt;=1:8,&gt;=1:16,&gt;=1:32,&gt;=1:64,&gt;=1:128 for ACWY Test Strains: Groups 1, 2, 3 and 4</measure>
    <time_frame>Before Vaccination 1, 1 Month after Vaccination 1, Before Vaccination 2, 1 Month after Vaccination 2</time_frame>
    <description>Describe ACWY response during Stage 1.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>hSBA GMTs for ACWY Test Strains: Groups 1, 2, 3 and 4</measure>
    <time_frame>Before Vaccination 1, 1 Month after Vaccination 1, Before Vaccination 2, 1 Month after Vaccination 2</time_frame>
    <description>Describe ACWY response during Stage 1.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With hSBA Titers &gt;=LLOQ for 4 Primary MenB Test Strains: Groups 1 and 3 combined, and Groups 2 and 4 combined</measure>
    <time_frame>Before Vaccination 1, 1 Month after Vaccination 1, Before Vaccination 2, 1 Month after Vaccination 2</time_frame>
    <description>Describe B response during Stage 1.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With hSBA Titers &gt;=1:4,&gt;=1:8,&gt;=1:16,&gt;=1:32,&gt;=1:64,&gt;=1:128 for 4 Primary MenB Test Strains: Groups 1 and 3 combined, and Groups 2 and 4 combined</measure>
    <time_frame>Before Vaccination 1, 1 Month after Vaccination 1, Before Vaccination 2, 1 Month after Vaccination 2</time_frame>
    <description>Describe B response during Stage 1.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>hSBA GMTs for 4 Primary MenB Test Strains: Groups 1 and 3 combined, and Groups 2 and 4 combined</measure>
    <time_frame>Before Vaccination 1, 1 Month after Vaccination 1, Before Vaccination 2, 1 Month after Vaccination 2</time_frame>
    <description>Describe B response during Stage 1.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With hSBA Titers &gt;=1:8 (or &gt;=LLOQ if higher) for ACWY Test Strains: Groups 1 and 2</measure>
    <time_frame>Before Vaccination 1, 1 Month after Vaccination 2, at Month 18, 30, and 42, and Before the Booster vaccination</time_frame>
    <description>Describe ACWY response during Stage 2 (Persistence)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With hSBA Titers &gt;=1:4,&gt;=1:8,&gt;=1:16,&gt;=1:32,&gt;=1:64,&gt;=1:128 for ACWY Test Strains: Groups 1 and 2</measure>
    <time_frame>Before Vaccination 1, 1 Month after Vaccination 2, at Month 18, 30, and 42, and Before the Booster vaccination</time_frame>
    <description>Describe ACWY response during Stage 2 (Persistence)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>hSBA GMTs for ACWY Test Strains: Groups 1 and 2</measure>
    <time_frame>Before Vaccination 1, 1 Month after Vaccination 2, at Month 18, 30, and 42, and Before the Booster vaccination</time_frame>
    <description>Describe ACWY response during Stage 2 (Persistence)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With hSBA Titers &gt;=LLOQ for 4 Primary MenB Test Strains: Group 1 and 2</measure>
    <time_frame>Before Vaccination 1, 1 Month after Vaccination 2, at Month 18, 30, and 42, and Before the Booster vaccination</time_frame>
    <description>Describe B response during Stage 2 (Persistence)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With hSBA Titers &gt;=1:4,&gt;=1:8,&gt;=1:16,&gt;=1:32,&gt;=1:64,&gt;=1:128 for 4 Primary MenB Test Strains: Groups 1 and 2</measure>
    <time_frame>Before Vaccination 1, 1 Month after Vaccination 2, at Month 18, 30, and 42, and Before the Booster vaccination</time_frame>
    <description>Describe B response during Stage 2 (Persistence)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>hSBA GMTs for 4 Primary MenB Test Strains: Groups 1 and 2</measure>
    <time_frame>Before Vaccination 1, 1 Month after Vaccination 2, at Month 18, 30, and 42, and Before the Booster vaccination</time_frame>
    <description>Describe B response during Stage 2 (Persistence)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With hSBA Titers &gt;=1:8 (or &gt;=LLOQ if higher) for ACWY Test Strains: Group 1</measure>
    <time_frame>1 Month after Vaccination 2, Before the Booster vaccination, and 1 Month after the Booster Vaccination</time_frame>
    <description>Describe ACWY response after MenABCWY booster</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With hSBA Titers &gt;=1:4,&gt;=1:8,&gt;=1:16,&gt;=1:32,&gt;=1:64,&gt;=1:128 for ACWY Test Strains: Group 1</measure>
    <time_frame>1 Month after Vaccination 2, Before the Booster vaccination, and 1 Month after the Booster Vaccination</time_frame>
    <description>Describe ACWY response after MenABCWY booster</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>hSBA GMTs for ACWY Test Strains: Group 1</measure>
    <time_frame>1 Month after Vaccination 2, Before the Booster vaccination, and 1 Month after the Booster Vaccination</time_frame>
    <description>Describe ACWY response after MenABCWY booster</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With hSBA Titers &gt;=LLOQ for 4 Primary MenB Test Strains: Group 1</measure>
    <time_frame>1 Month after Vaccination 2, Before the Booster vaccination, and 1 Month after the Booster Vaccination</time_frame>
    <description>Describe B response after MenABCWY booster</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With hSBA Titers &gt;=1:4,&gt;=1:8,&gt;=1:16,&gt;=1:32,&gt;=1:64,&gt;=1:128 for 4 Primary MenB Test Strains: Group 1</measure>
    <time_frame>1 Month after Vaccination 2, Before the Booster vaccination, and 1 Month after the Booster Vaccination</time_frame>
    <description>Describe B response after MenABCWY booster</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>hSBA GMTs for 4 Primary MenB Test Strains: Group 1</measure>
    <time_frame>1 Month after Vaccination 2, Before the Booster vaccination, and 1 Month after the Booster Vaccination</time_frame>
    <description>Describe B response after MenABCWY booster</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With &gt;=4 Fold Rise in hSBA for 4 Primary MnB Strains and Composite Response (hSBA &gt;=LLOQ for All 4 Primary MnB Strains Combined) for Group 1</measure>
    <time_frame>1 Month after Vaccination 2, Before the Booster vaccination, and 1 Month after the Booster Vaccination</time_frame>
    <description>Describe B response after MenABCWY booster</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With hSBA Titers &gt;=LLOQ for 4 Primary MenB Test Strains: Group 2</measure>
    <time_frame>1 Month after Vaccination 2, Before the Booster vaccination, and 1 Month after the Booster Vaccination</time_frame>
    <description>Describe B response after Trumenba booster</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With hSBA Titers &gt;=1:4,&gt;=1:8,&gt;=1:16,&gt;=1:32,&gt;=1:64,&gt;=1:128 for 4 Primary MenB Test Strains: Group 2</measure>
    <time_frame>1 Month after Vaccination 2, Before the Booster vaccination, and 1 Month after the Booster Vaccination</time_frame>
    <description>Describe B response after Trumenba booster</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>hSBA GMTs for 4 Primary MenB Test Strains: Group 2</measure>
    <time_frame>1 Month after Vaccination 2, Before the Booster vaccination, and 1 Month after the Booster Vaccination</time_frame>
    <description>Describe B response after Trumenba booster</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With &gt;=4 Fold Rise in hSBA for 4 Primary MnB Strains and Composite Response (hSBA &gt;=LLOQ for All 4 Primary MnB Strains Combined) for Group 2</measure>
    <time_frame>1 Month after Vaccination 2, Before the Booster vaccination, and 1 Month after the Booster Vaccination</time_frame>
    <description>Describe B response after Trumenba booster</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Reporting Local Reactions (LRs) Within 7 Days After First Vaccination for Groups 1 and 3</measure>
    <time_frame>Within 7 Days after first vaccination</time_frame>
    <description>Describe local reactions after first dose of MenABCWY</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Reporting Local Reactions (LRs) Within 7 Days After Second Vaccination for Groups 1 and 3</measure>
    <time_frame>Within 7 Days after second vaccination</time_frame>
    <description>Describe local reactions after second dose of MenABCWY</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Reporting Local Reactions (LRs) Within 7 Days After Booster Vaccination for Groups 1 and 2</measure>
    <time_frame>Within 7 Days after booster vaccination</time_frame>
    <description>Describe local reactions after booster</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Reporting Systemic Events (SEs) and Antipyretic Use Within 7 Days After First Vaccination for Groups 1 and 3</measure>
    <time_frame>Within 7 Days of the first vaccination</time_frame>
    <description>Describe systemic events and use of anti-pyretic medication after first dose of MenABCWY.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Reporting Systemic Events (SEs) and Antipyretic Use Within 7 Days After Second Vaccination for Groups 1 and 3</measure>
    <time_frame>Within 7 Days of the second vaccination</time_frame>
    <description>Describe systemic events and use of anti-pyretic medication after second dose of MenABCWY.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Reporting Systemic Events (SEs) and Antipyretic Use Within 7 Days After Booster Vaccination for Groups 1 and 2</measure>
    <time_frame>Within 7 Days of the booster vaccination</time_frame>
    <description>Describe systemic events and use of anti-pyretic medication after booster.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With at Least 1 Serious Adverse Event (SAE) Within 30 Days After First Vaccination for Groups 1 and 3</measure>
    <time_frame>Within 30 days after first vaccination</time_frame>
    <description>Describe SAE frequency after first dose of MenABCWY.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With at Least 1 Serious Adverse Event (SAE) Within 30 Days After Second Vaccination for Groups 1 and 3</measure>
    <time_frame>Within 30 days after second vaccination</time_frame>
    <description>Describe SAE frequency after second dose of MenABCWY.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With at Least 1 Serious Adverse Event (SAE) Within 30 Days After Booster Vaccination for Groups 1 and 2</measure>
    <time_frame>Within 30 days after booster vaccination</time_frame>
    <description>Describe SAE frequency after booster.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With at Least 1 Serious Adverse Event (SAE) During the Stage 1 Vaccination Phase for Groups 1 and 3</measure>
    <time_frame>From the first vaccination up to 1 month after the second vaccination</time_frame>
    <description>Describe SAE frequency during the Stage 1 vaccination phase in the MenABCWY vaccination groups.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With at Least 1 Serious Adverse Event (SAE) During the Stage 1 Follow-up Phase for Groups 1 and 3</measure>
    <time_frame>From 1 month after second vaccination up to 6 months after the second vaccination</time_frame>
    <description>Describe SAE frequency during the Stage 1 follow-up phase in the MenABCWY vaccination groups.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With at Least 1 Serious Adverse Event (SAE) Throughout Stage 1 of the Study for Groups 1 and 3</measure>
    <time_frame>From the first vaccination up to 6 months after the second vaccination</time_frame>
    <description>Describe SAE frequency during the Stage 1 in the MenABCWY vaccination groups.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With at Least 1 Serious Adverse Event (SAE) During the Booster Vaccination Phase for Groups 1 and 2</measure>
    <time_frame>From the booster vaccination up to 1 month after the booster vaccination</time_frame>
    <description>Describe SAE frequency during the Booster vaccination phase.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With at Least 1 Serious Adverse Event (SAE) During the Booster Follow-up Phase for Groups 1 and 2</measure>
    <time_frame>From 1 month after booster vaccination up to 6 months after the booster vaccination</time_frame>
    <description>Describe SAE frequency during the Booster follow-up phase.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With at Least 1 Serious Adverse Event (SAE) from the booster vaccination to 6 months after the booster vaccination for Groups 1 and 2</measure>
    <time_frame>From the booster vaccination up to 6 months after the booster vaccination</time_frame>
    <description>Describe SAE frequency following the Booster.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With at Least 1 Medically Attended AE Within 30 Days After First Vaccination for Groups 1 and 3</measure>
    <time_frame>Within 30 days after first vaccination</time_frame>
    <description>Describe MAE frequency after first dose of MenABCWY.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With at Least 1 Medically Attended AE Within 30 Days After Second Vaccination for Groups 1 and 3</measure>
    <time_frame>Within 30 days after second vaccination</time_frame>
    <description>Describe MAE frequency after second dose of MenABCWY.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With at Least 1 Medically Attended AE Within 30 Days After Booster Vaccination for Groups 1 and 2</measure>
    <time_frame>Within 30 days after booster vaccination</time_frame>
    <description>Describe MAE frequency after booster</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With at Least 1 Medically Attended AE Within 30 Days After Any Vaccination for Groups 1 and 3</measure>
    <time_frame>Within 30 days after any vaccination in Stage 1</time_frame>
    <description>Describe MAE frequency after any dose of MenABCWY in Stage 1</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With at Least 1 Medically Attended AE During the Stage 1 Vaccination Phase for Groups 1 and 3</measure>
    <time_frame>From the first vaccination up to 1 month after the second vaccination</time_frame>
    <description>Describe MAE frequency during the Stage 1 vaccination phase in the MenABCWY vaccination groups.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With at Least 1 Medically Attended AE During the Stage 1 Follow-up Phase for Groups 1 and 3</measure>
    <time_frame>From 1 month after second vaccination up to 6 months after the second vaccination</time_frame>
    <description>Describe MAE frequency during the Stage 1 follow-up phase in the MenABCWY vaccination groups.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With at Least 1 Medically Attended AE Throughout Stage 1 of the Study for Groups 1 and 3</measure>
    <time_frame>From the first vaccination up to 6 months after the second vaccination</time_frame>
    <description>Describe MAE frequency during the Stage 1 in the MenABCWY vaccination groups.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With at Least 1 Medically Attended AE During the Booster Vaccination Phase for Groups 1 and 2</measure>
    <time_frame>From the booster vaccination up to 1 month after the booster vaccination</time_frame>
    <description>Describe MAE frequency during the Booster vaccination phase.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With at Least 1 Medically Attended AE During the Booster Follow-up Phase for Groups 1 and 2</measure>
    <time_frame>From 1 month after booster vaccination up to 6 months after the booster vaccination</time_frame>
    <description>Describe MAE frequency during the Booster follow-up phase.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With at Least 1 Medically Attended AE from the booster vaccination to 6 months after the booster vaccination for Groups 1 and 2</measure>
    <time_frame>From the booster vaccination up to 6 months after the booster vaccination</time_frame>
    <description>Describe MAE frequency following the Booster.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With at Least 1 Newly Diagnosed Chronic Medical Condition Within 30 Days After First Vaccination for Groups 1 and 3</measure>
    <time_frame>Within 30 days after first vaccination</time_frame>
    <description>Describe NDCMC frequency after first dose of MenABCWY.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With at Least 1 Newly Diagnosed Chronic Medical Condition Within 30 Days After Second Vaccination for Groups 1 and 3</measure>
    <time_frame>Within 30 days after second vaccination</time_frame>
    <description>Describe NDCMC frequency after second dose of MenABCWY.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With at Least 1 Newly Diagnosed Chronic Medical Condition Within 30 Days After Booster Vaccination for Groups 1 and 2</measure>
    <time_frame>Within 30 days after booster vaccination</time_frame>
    <description>Describe NDCMC frequency after booster</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With at Least 1 Newly Diagnosed Chronic Medical Condition Within 30 Days After Any Vaccination for Groups 1 and 3</measure>
    <time_frame>Within 30 days after any vaccination in Stage 1</time_frame>
    <description>Describe NDCMC frequency after any dose of MenABCWY in Stage 1</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With at Least 1 Newly Diagnosed Chronic Medical Condition During the Stage 1 Vaccination Phase for Groups 1 and 3</measure>
    <time_frame>From the first vaccination up to 1 month after the second vaccination</time_frame>
    <description>Describe NDCMC frequency during the Stage 1 vaccination phase in the MenABCWY vaccination groups.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With at Least 1 Newly Diagnosed Chronic Medical Condition During the Stage 1 Follow-up Phase for Groups 1 and 3</measure>
    <time_frame>From 1 month after second vaccination up to 6 months after the second vaccination</time_frame>
    <description>Describe NDCMC frequency during the Stage 1 follow-up phase in the MenABCWY vaccination groups.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With at Least 1 Newly Diagnosed Chronic Medical Condition Throughout Stage 1 of the Study for Groups 1 and 3</measure>
    <time_frame>From the first vaccination up to 6 months after the second vaccination</time_frame>
    <description>Describe NDCMC frequency during the Stage 1 in the MenABCWY vaccination groups.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With at Least 1 Newly Diagnosed Chronic Medical Condition During the Booster Vaccination Phase for Groups 1 and 2</measure>
    <time_frame>From the booster vaccination up to 1 month after the booster vaccination</time_frame>
    <description>Describe NDCMC frequency during the Booster vaccination phase.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With at Least 1 Newly Diagnosed Chronic Medical Condition During the Booster Follow-up Phase for Groups 1 and 2</measure>
    <time_frame>From 1 month after booster vaccination up to 6 months after the booster vaccination</time_frame>
    <description>Describe NDCMC frequency during the Booster follow-up phase.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With at Least 1 Newly Diagnosed Chronic Medical Condition from the booster vaccination to 6 months after the booster vaccination for Groups 1 and 2</measure>
    <time_frame>From the booster vaccination up to 6 months after the booster vaccination</time_frame>
    <description>Describe NDCMC frequency during the Stage 1 in the MenABCWY vaccination groups.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With at Least 1 AE Within 30 Days After First Vaccination for Groups 1 and 3</measure>
    <time_frame>Within 30 days after first vaccination</time_frame>
    <description>Describe AE frequency after first dose of MenABCWY.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With at Least 1 AE Within 30 Days After Second Vaccination for Groups 1 and 3</measure>
    <time_frame>Within 30 days after second vaccination</time_frame>
    <description>Describe AE frequency after second dose of MenABCWY.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With at Least 1 AE Within 30 Days After Booster Vaccination for Groups 1 and 2</measure>
    <time_frame>Within 30 days after booster vaccination</time_frame>
    <description>Describe AE frequency after booster</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With at Least 1 AE Within 30 Days After Any Vaccination for Groups 1 and 3</measure>
    <time_frame>Within 30 days after any vaccination in Stage 1</time_frame>
    <description>Describe AE frequency after any dose of MenABCWY in Stage 1</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With at Least 1 AE Durng the Stage 1 Vaccination Phase for Groups 1 and 3</measure>
    <time_frame>From the first vaccination up to 1 month after the second vaccination</time_frame>
    <description>Describe AE frequency during the Stage 1 vaccination phase in the MenABCWY vaccination groups.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With at Least 1 AE During the Booster Vaccination Phase for Groups 1 and 2</measure>
    <time_frame>From the booster vaccination up to 1 month after the booster vaccination</time_frame>
    <description>Describe AE frequency during the Booster vaccination phase.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Reporting at Least 1 Immediate Adverse Event (AE) After First Vaccination for Groups 1 and 3</measure>
    <time_frame>Within 30 minutes after first vaccination</time_frame>
    <description>Describe immediate AE frequency after first dose of MenABCWY.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Reporting at Least 1 Immediate Adverse Event (AE) After Second Vaccination for Groups 1 and 3</measure>
    <time_frame>Within 30 minutes after second vaccination</time_frame>
    <description>Describe immediate AE frequency after second dose of MenABCWY.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Reporting at Least 1 Immediate Adverse Event (AE) After Booster Vaccination for Groups 1 and 2</measure>
    <time_frame>Within 30 minutes after booster vaccination</time_frame>
    <description>Describe immediate AE frequency after MenABCWY booster.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Days Participants Missed School or Work Due to AE During the Stage 1 Vaccination Phase for Groups 1 and 3</measure>
    <time_frame>From the first vaccination up to 1 month after the second vaccination</time_frame>
    <description>Describe the number of days missed from school or work due to an AE during the Stage 1 vaccination phase in MenABCWY vaccination groups.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Days Participants Missed School or Work Due to AE During the Booster Vaccination Phase for Groups 1 and 2</measure>
    <time_frame>From the booster vaccination up to 1 month after the booster vaccination</time_frame>
    <description>Describe the number of days missed from school or work due to an AE during the booster vaccination phase.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With at Least 1 Serious Adverse Event (SAE) Within 30 Days After Any Vaccination for Groups 1 and 3</measure>
    <time_frame>Within 30 days after any vaccination in Stage 1</time_frame>
    <description>Describe SAE frequency after any MenABCWY dose in Stage 1.</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">1610</enrollment>
  <condition>Meningococcal Vaccine</condition>
  <arm_group>
    <arm_group_label>Group 1 (ACWY Naive subjects, MenABCWY/Saline)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>ACWY Naive subjects, MenABCWY/Saline</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 2 (ACWY Naive subjects, rLP2086/MenACWY-CRM)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>ACWY Naive subjects, rLP2086/MenACWY-CRM</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 3 (ACWY Experienced subjects, MenABCWY/Saline)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>ACWY Experienced subjects, MenABCWY/Saline</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 4 (ACWY Experienced subjects, rLP2086/MenACWY-CRM)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>ACWY Experienced subjects, rLP2086/MenACWY-CRM</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>MenABCWY</intervention_name>
    <description>N meningitidis group A, B, C, W, and Y vaccine</description>
    <arm_group_label>Group 1 (ACWY Naive subjects, MenABCWY/Saline)</arm_group_label>
    <arm_group_label>Group 3 (ACWY Experienced subjects, MenABCWY/Saline)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Saline</intervention_name>
    <description>Placebo</description>
    <arm_group_label>Group 1 (ACWY Naive subjects, MenABCWY/Saline)</arm_group_label>
    <arm_group_label>Group 3 (ACWY Experienced subjects, MenABCWY/Saline)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>rLP2086</intervention_name>
    <description>Bivalent recombinant lipoprotein 2086 vaccine</description>
    <arm_group_label>Group 2 (ACWY Naive subjects, rLP2086/MenACWY-CRM)</arm_group_label>
    <arm_group_label>Group 4 (ACWY Experienced subjects, rLP2086/MenACWY-CRM)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>MenACWY-CRM</intervention_name>
    <description>meningococcal group A, C, W-135, and Y conjugate vaccine</description>
    <arm_group_label>Group 2 (ACWY Naive subjects, rLP2086/MenACWY-CRM)</arm_group_label>
    <arm_group_label>Group 4 (ACWY Experienced subjects, rLP2086/MenACWY-CRM)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male or female subject aged &gt;=10 and &lt;26 years at the time of enrollment.

          -  Healthy subject as determined by medical history, physical examination, and judgment
             of the investigator.

          -  Negative urine pregnancy test for all female subjects.

          -  Subjects who have not received, or who have received no more than 1 prior dose within
             the past 4 years, of a vaccine containing 1 or more ACWY serogroup

        Exclusion Criteria:

          -  Previous vaccination with any meningococcal serogroup B or purely polysaccaride
             (nonconjugate) meningococcal vaccine.

          -  Subjects receiving any allergen immunotherapy with a nonlicensed product or receiving
             allergen immunotherapy with a licensed product and are not on stable maintenance
             doses.

          -  A known or suspected defect of the immune system that would prevent an immune response
             to the vaccine, such as subjects with congenital or acquired defects in B cell
             function, those receiving chronic systemic (oral, intravenous, or intramuscular)
             corticosteroid therapy, or those receiving immunosuppressive therapy. Subjects in the
             United States with terminal complement deficiency are excluded from participation in
             this study.

          -  Significant neurological disorder or history of seizure (excluding simple febrile
             seizure).

          -  Current chronic use of systemic antibiotics.

          -  Received any investigational vaccines, drugs, or devices within 28 days before
             administration of the first study vaccination.

          -  Any neuroinflammatory or autoimmune condition, including, but not limited to,
             transverse myelitis, uveitis, optic neuritis, and multiple sclerosis.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>10 Years</minimum_age>
    <maximum_age>25 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pfizer CT.gov Call Center</last_name>
    <role>Study Director</role>
    <affiliation>Pfizer</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Alabama Clinical Therapeutics, LLC / Birmingham Pediatric Associates</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35205</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Optimal Research</name>
      <address>
        <city>Huntsville</city>
        <state>Alabama</state>
        <zip>35802</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Research Advantage, Inc./Fountain Hills Family Practice, P.C.</name>
      <address>
        <city>Fountain Hills</city>
        <state>Arizona</state>
        <zip>85268</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Research Consortium</name>
      <address>
        <city>Tempe</city>
        <state>Arizona</state>
        <zip>85283</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Harrisburg Family Medical Center</name>
      <address>
        <city>Harrisburg</city>
        <state>Arkansas</state>
        <zip>72432</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Paradigm Clinical Research Centers, Inc.</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92117</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>California Research Foundation</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92123</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kaiser Permanente Santa Clara</name>
      <address>
        <city>Santa Clara</city>
        <state>California</state>
        <zip>95051</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Avail Clinical Research, LLC</name>
      <address>
        <city>DeLand</city>
        <state>Florida</state>
        <zip>32720</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Health Awareness, Inc.</name>
      <address>
        <city>Jupiter</city>
        <state>Florida</state>
        <zip>33458</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Optimal Research, LLC</name>
      <address>
        <city>Melbourne</city>
        <state>Florida</state>
        <zip>32934</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Meridian Clinical Research LLC</name>
      <address>
        <city>Savannah</city>
        <state>Georgia</state>
        <zip>31406</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Optimal Research</name>
      <address>
        <city>Peoria</city>
        <state>Illinois</state>
        <zip>61614</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Heartland Research Associates, LLC</name>
      <address>
        <city>Newton</city>
        <state>Kansas</state>
        <zip>67114</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Heartland Research Associates, LLC</name>
      <address>
        <city>Wichita</city>
        <state>Kansas</state>
        <zip>67205</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Heartland Research Associates, LLC</name>
      <address>
        <city>Wichita</city>
        <state>Kansas</state>
        <zip>67207</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kentucky Pediatric/Adult Research</name>
      <address>
        <city>Bardstown</city>
        <state>Kentucky</state>
        <zip>40004</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Horizon Research Group of Opelousas, LLC</name>
      <address>
        <city>Eunice</city>
        <state>Louisiana</state>
        <zip>70535</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ACC Pediatric Research</name>
      <address>
        <city>Haughton</city>
        <state>Louisiana</state>
        <zip>71037</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Research Advantage, Inc./Prairie Fields Family Medicine, PC</name>
      <address>
        <city>Fremont</city>
        <state>Nebraska</state>
        <zip>68025</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Meridian Clinical Research</name>
      <address>
        <city>Norfolk</city>
        <state>Nebraska</state>
        <zip>68701</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Meridian Clinical Research, LLC</name>
      <address>
        <city>Omaha</city>
        <state>Nebraska</state>
        <zip>68134</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>United Medical Associates</name>
      <address>
        <city>Binghamton</city>
        <state>New York</state>
        <zip>13901</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Regional Clinical Research, Inc</name>
      <address>
        <city>Endwell</city>
        <state>New York</state>
        <zip>13760</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rochester Clinical Research, Inc.</name>
      <address>
        <city>Rochester</city>
        <state>New York</state>
        <zip>14609</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Capitol Pediatrics &amp; Adolescent Center PLLC</name>
      <address>
        <city>Raleigh</city>
        <state>North Carolina</state>
        <zip>27609</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sterling Research Group, Ltd.</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45246</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rapid Medical Research, Inc</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44122</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Aventiv Research Inc.</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43213</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ohio Pediatric Research Association, Inc.</name>
      <address>
        <city>Dayton</city>
        <state>Ohio</state>
        <zip>45414</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lynn Health Science Institute</name>
      <address>
        <city>Oklahoma City</city>
        <state>Oklahoma</state>
        <zip>73112</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Liberty Family Practice</name>
      <address>
        <city>Erie</city>
        <state>Pennsylvania</state>
        <zip>16508</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Charleston Pediatrics, PA</name>
      <address>
        <city>Charleston</city>
        <state>South Carolina</state>
        <zip>29403</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Coastal Carolina Research Center</name>
      <address>
        <city>Mount Pleasant</city>
        <state>South Carolina</state>
        <zip>29464</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>PMG Research of Charleston, LLC</name>
      <address>
        <city>Mount Pleasant</city>
        <state>South Carolina</state>
        <zip>29464</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Meridian Clinical Research</name>
      <address>
        <city>Dakota Dunes</city>
        <state>South Dakota</state>
        <zip>57049</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Internal Medicine and Pediatric Associates of Bristol, PC</name>
      <address>
        <city>Bristol</city>
        <state>Tennessee</state>
        <zip>37620</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>PMG Research of Bristol, LLC</name>
      <address>
        <city>Bristol</city>
        <state>Tennessee</state>
        <zip>37620</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Holston Medical Group</name>
      <address>
        <city>Kingsport</city>
        <state>Tennessee</state>
        <zip>37660</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Research Associates, Inc.</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37203</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Benchmark Research</name>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <zip>78705</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Texas Health Care, PLLC</name>
      <address>
        <city>Fort Worth</city>
        <state>Texas</state>
        <zip>76104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ventavia Research Group, LLC</name>
      <address>
        <city>Fort Worth</city>
        <state>Texas</state>
        <zip>76104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Benchmark Research</name>
      <address>
        <city>Fort Worth</city>
        <state>Texas</state>
        <zip>76135</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Health First Medical Group</name>
      <address>
        <city>Fort Worth</city>
        <state>Texas</state>
        <zip>76135</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>North Texas Family Medicine</name>
      <address>
        <city>Plano</city>
        <state>Texas</state>
        <zip>75093</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Trials of Texas, Inc.</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>J. Lewis Research Inc. / Foothill Family Clinic Draper</name>
      <address>
        <city>Draper</city>
        <state>Utah</state>
        <zip>84020</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>J. Lewis Research, Inc. / Foothill Family Clinic</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84109</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>J. Lewis Research, Inc. / Foothill Family Clinic South</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84121</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>J. Lewis Research, Inc. / Jordan River Family Medicine</name>
      <address>
        <city>South Jordan</city>
        <state>Utah</state>
        <zip>84095</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>PI-Coor Clinical Research, LLC</name>
      <address>
        <city>Burke</city>
        <state>Virginia</state>
        <zip>22015</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pediatric Research of Charlottesville, LLC</name>
      <address>
        <city>Charlottesville</city>
        <state>Virginia</state>
        <zip>22902</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ordinace praktickeho lekare pro deti a dorost</name>
      <address>
        <city>Jindrichuv Hradec</city>
        <zip>377 01</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>MEDICENTRUM 6 s.r.o. - Ordinace praktickeho lekare pro deti a dorost</name>
      <address>
        <city>Praha 6</city>
        <zip>160 00</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Espoo Vaccine Research Clinic</name>
      <address>
        <city>Espoo</city>
        <zip>02230</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Helsinki South Vaccine Research Clinic</name>
      <address>
        <city>Helsinki</city>
        <zip>00100</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Helsinki East Vaccine Research Clinic</name>
      <address>
        <city>Helsinki</city>
        <zip>00930</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Järvenpää Vaccine Research Clinic</name>
      <address>
        <city>Järvenpää</city>
        <zip>04400</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kokkola Vaccine Research Clinic</name>
      <address>
        <city>Kokkola</city>
        <zip>67100</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Oulu Vaccine Research Clinic</name>
      <address>
        <city>Oulu</city>
        <zip>90220</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pori Vaccine Research Clinic</name>
      <address>
        <city>Pori</city>
        <zip>28100</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Seinajoki Vaccine Research Clinic</name>
      <address>
        <city>Seinajoki</city>
        <zip>60100</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tampere Vaccine Research Clinic</name>
      <address>
        <city>Tampere</city>
        <zip>33100</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Turku Vaccine Research Clinic</name>
      <address>
        <city>Turku</city>
        <zip>20520</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Jerzy Brzostek Prywatny Gabinet Lekarski</name>
      <address>
        <city>Debica</city>
        <zip>39-200</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Oddzial Pediatrii i Neurologii Dzieciecej, Krakowski Szpital Specjalistyczny im. Jana Pawla II</name>
      <address>
        <city>Krakow</city>
        <zip>31-202</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hanna Czajka Indywidualna Specjalistyczna Praktyka Lekarska</name>
      <address>
        <city>Krakow</city>
        <zip>31-302</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Czechia</country>
    <country>Finland</country>
    <country>Poland</country>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://trialinfoemail.pfizer.com/pages/landing.aspx?StudyID=B1971057&amp;StudyName=A%20Phase%203%2C%20Randomized%2C%20Active-controlled%2C%20Observer-blinded%20Study%20To%20Assess%20The%20Immunogenicity%2C%20Safety%2C%20And%20Tolerability%20Of%20Bivalent%20rLP2086%20When%20Administered%20As%20A%202-dose%20Regimen%20And%20A%20First-in-human%20Study%20To%20Describe%20The%20Immunogenicity%2C%20Safety%2C%20And%20Tolerability%20Of%20A%20Bivalent%20rLP2086%E2%80%93containing%20Pentavalent%20Vaccine%20%28Menabcwy%29%20In%20Healthy%20Subjects%20greater%20than%3D10%20To%20less%20than26%20Years%20Of%20Age.</url>
    <description>To obtain contact information for a study center near you, click here.</description>
  </link>
  <link>
    <url>https://trialinfoemail.pfizer.com/pages/landing.aspx?StudyID=B1971057&amp;StudyName=A+Phase+3%2C+Randomized%2C+Active-controlled%2C+Observer-blinded+Study+To+Assess+The+Immunogenicity%2C+Safety%2C+And+Tolerability+Of+Bivalent+Rlp2086+When+Administered+As+A+2-dose+Regimen+And+A+First-in-human+Study+To+Describe+The+Immunogenicity%2C+Safety%2C+And+Tolerability+Of+A+Bivalent+Rlp2086%E2%80%93containing+Pentavalent+Vaccine+%28menabcwy%29+In+Healthy+Subjectsgreater+than%3D10+To+less+than26+Years+Of+Age</url>
    <description>To obtain contact information for a study center near you, click here.</description>
  </link>
  <verification_date>February 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 26, 2017</study_first_submitted>
  <study_first_submitted_qc>April 26, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">May 1, 2017</study_first_posted>
  <last_update_submitted>February 13, 2018</last_update_submitted>
  <last_update_submitted_qc>February 13, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">February 14, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaccines</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Information relating to our policy on data sharing and the process for requesting data can be found at the following link: http://www.pfizer.com/research/clinical_trials/trial_data_and_results/data_requests</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

